SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    zur Hausen H. 1991. Viruses in human cancers. Science 1991;254: 116773.
  • 2
    Matsukura T, Sugase M. Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions. Int J Cancer 1995;61: 1322.
  • 3
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354: 205.
  • 4
    Zehbe I, Rylander E, Edlund K, et al. Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. Virchows Arch 1996;428: 1517.
  • 5
    Zehbe I, Wilander E. Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. J Pathol 1997;181: 2705.
  • 6
    Mansur CP, Androphy EJ. Cellular transformation by papillomavirus oncoproteins. Biochim Biophys Acta 1993;1155: 32345.
  • 7
    Tommasino M, Crawford L. Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays 1995;17: 50918.
  • 8
    Londesborough P, Ho L, Terry G, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69: 3648.
  • 9
    Zehbe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms [Letter]. Lancet 1998;352: 14412.
  • 10
    Zehbe I, Wilander E, Delius H, et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 1998;58: 82933.
  • 11
    Xi LF, Critchlow CW, Wheeler CM, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res 1998;58: 383944.
  • 12
    Xi LF, Demers GW, Koutsky LA, et al. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 1995;172: 74755.
  • 13
    Xi LF, Koutsky LA, Galloway DA, et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia [see comments]. J Natl Cancer Inst 1997;89: 796802.
  • 14
    Villa LL, Sichero L, Rahal P, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81: 295968.
  • 15
    Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001;93: 3158.
  • 16
    Zehbe I, Voglino G, Wilander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001;61: 60811.
  • 17
    Seedorf K, Krammer G, Durst M, et al. Human papillomavirus type 16 DNA sequence. Virology 1985;145: 1815.
  • 18
    Allen M, Kalantari M, Ylitalo N, et al. 1996. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 1996;48: 327.
  • 19
    Imaniski T, Akaza T, Kimura A, et al. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: AizawaM, SasazukiT, eds. HLA 1991. Proceedings of the 11th International Histocompatibility Workshop and Conference, vol. 1. Oxford University Press, Oxford, UK: 1992.
  • 20
    Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71: 246372.
  • 21
    Zehbe I, Tommasino M. The biological significance of human papillomavirus type 16 variants for the development of cervical neoplasia. Papillomavirus Rep 1999;10: 10516.
  • 22
    Nindl I, Rindfleisch K, Lotz B, et al. 1999. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 1999;82: 2037.
  • 23
    Tornesello ML, Buonaguro FM, Meglio A, et al. Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients. J Gen Virol 1997;78: 2199208.
  • 24
    Bontkes HJ, van Duin M, de Gruijl TD, et al. 1998. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 1998;78: 16671.
  • 25
    van Duin M, Snijders PJ, Vossen MT, et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 2000;81: 31725.
  • 26
    Brady CS, Duggan-Keen MF, Davidson JA, et al. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters. J Gen Virol 1999;80: 323340.
  • 27
    Cuzick J, Terry G, Ho L, et al. 2000. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000;82: 134852.
  • 28
    Helland A, Borresen AL, Kristensen G, et al. DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis. Cancer Epidemiol Biomarkers Prev 1994;3: 47986.
  • 29
    Sastre-Garau X, Loste MN, Vincent-Salomon A, et al. 1996. Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer 1996;69: 15964.
  • 30
    Nakagawa M, Stites DP, Patel S, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000;182: 5958.